Wabtec remains a high-quality industrial company with strong market share and robust margins. Despite missing Q3 revenue expectations, the company delivered solid margin expansion and operating results, with deferred deliveries expected to recover next quarter. Healthy North American rail fundamentals and international projects like Simandou support long-term growth. While valuation looks high on discounted cash flow, it is more attractive on EV/EBITDA, making the recent pullback a potential entry point for patient investors.
Wabtec's recent Q3 results provide context for the Industrials sector's market snapshot on Pluang as of Oct 24, 2026 01:11 WIB: Among 135 priced US Industrials stocks, 54 rose and 80 fell. Notably, ODFL traded at USD 182.53 with 100% buy orders and a typical hold time of 77 days, contrasting with QXO at USD 10.47 down 4.99% and SMX at USD 1.76 with 98% sell orders, reflecting varied investor sentiment within the sector.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
